| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 4.36 MB | Adobe PDF |
Advisor(s)
Abstract(s)
SARS-CoV-2 infection has been a major threat to human health and a huge challenge to Medicine. In only two years, COVID-19 affected >350 million people, causing >5.6 million deaths. Chronic inflammatory states, such as diabetes or obesity, are known risk factors for COVID-19 poorest outcomes, with a higher risk for disease severity and greater mortality. Metformin remains on the first line of the management of hyperglycemia in type 2 diabetes. Through its anti-inflammatory and immunomodulatory mechanisms, metformin appears as an opportunity to control the dysregulated cytokine storm secondary to SARS-CoV-2 infection. Recent studies point towards a potential protective role of metformin in the course of COVID-19, showing that current or previous treatment with metformin associates with better outcomes.
Description
Keywords
COVID-19 Diabetes Metformin Mortality SARS-CoV-2 Severity
Citation
Pedrosa AR, Martins DC, Rizzo M, Silva-Nunes J. Metformin in SARS-CoV-2 infection: a hidden path - from altered inflammation to reduced mortality (a review from the literature). J Diabetes Complications. 2023;37(2):108391. [Online ahead of print].
Publisher
Elsevier